ArriVent BioPharma, Inc. (AVBP) Financials
AVBP Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 394.7 million | 27.9 million |
| March 31, 2026 | 349.3 million | 25.3 million |
| Dec. 31, 2025 | 333.2 million | 25.9 million |
| Sept. 30, 2025 | 326.6 million | 21.6 million |
AVBP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -39.6 million | 6.7 million |
| March 31, 2026 | -41.9 million | 5.5 million |
| Dec. 31, 2025 | -30.7 million | 3.2 million |
| Sept. 30, 2025 | -35.8 million | 3.7 million |
AVBP Net Income
No data available :(
AVBP Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 373.1 million | 33000 | 318000 |
| March 31, 2026 | 326.4 million | - | 419000 |
| Dec. 31, 2025 | 312.8 million | - | 14000 |
| Sept. 30, 2025 | 300.3 million | - | 56000 |
AVBP Shares Outstanding
AVBP Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 42.3 million | 10.4 million | - |
| March 31, 2026 | - | 37.6 million | 8.5 million | - |
| Dec. 31, 2025 | - | 32.2 million | 6.6 million | - |
| Sept. 30, 2025 | - | 32.2 million | 6.1 million | - |
AVBP Cost of Revenue
No data available :(
AVBP
Price: $16.06
52 week price:
Earnings Per Share: -3.55 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 1.3 billion